You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 10, 2024

Details for New Drug Application (NDA): 022115


✉ Email this page to a colleague

« Back to Dashboard


NDA 022115 describes LAMICTAL XR, which is a drug marketed by Glaxosmithkline Llc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the LAMICTAL XR profile page.

The generic ingredient in LAMICTAL XR is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
Summary for 022115
Tradename:LAMICTAL XR
Applicant:Glaxosmithkline Llc
Ingredient:lamotrigine
Patents:1
Suppliers and Packaging for NDA: 022115
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115 NDA GlaxoSmithKline LLC 0173-0754 0173-0754-00 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0754-00)
LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115 NDA GlaxoSmithKline LLC 0173-0755 0173-0755-00 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0755-00)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength25MG
Approval Date:May 29, 2009TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jun 14, 2028Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength50MG
Approval Date:May 29, 2009TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jun 14, 2028Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength100MG
Approval Date:May 29, 2009TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jun 14, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022115

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-001 May 29, 2009 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-006 Jun 21, 2011 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-003 May 29, 2009 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-004 May 29, 2009 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-005 Apr 14, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.